Recent

% | $
Quotes you view appear here for quick access.

Isis Pharmaceuticals, Inc. Message Board

  • dinepat203 dinepat203 Nov 28, 2012 10:14 AM Flag

    60K SHORT WAITING STOP LOSS?

    GOOD TRY....

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • If approved, Kynamro/mipomersen will be marketed by Sanofi’s Genzyme unit, a power play in rare diseases.

      While the FDA seems pleased with the risk/benefit profile of lomitapide for HoFH, there is always the risk of a “chemistry, manufacturing, and controls” or “CMC” issue delaying approval. Also, AEGR intends to market the drug alone in the US and EU – since the company has no commercial experience, there remains some execution risk until we see how the product launch and potential competitive positioning with mipomersen proceeds.

      Sentiment: Strong Buy

 
ISIS
54.40-0.38(-0.70%)Jul 28 4:00 PMEDT